Jefferies raised the firm’s price target on ImmunityBio (IBRX) to $9 from $8 and keeps a Buy rating on the shares. The firm believes ImmunityBio is in execution mode to continue expanding the company’s geographic and commercial presence and to advance the pipeline, and today’s EMA conditional marketing authorization recommendation for Anktiva in NMIBC-CIS builds on existing approvals in the U.S. and U.K. The company is continuing regulatory dialogue on the papillary disease and also awaiting NCCN guideline decision and BCG-naive data in the second half of 2026 could be another label expansion opportunity, Jefferies adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio’s Strategic Advancements and Market Potential Drive Buy Rating
- ImmunityBio Gains EMA Nod for ANKTIVA® in Europe
- ImmunityBio: EMA recommends marketing authorization in EU for ANKTIVA with BCG
- ImmunityBio Reports Revenue Surge Amid Financial Challenges
- ImmunityBio reports Q3 EPS (7c), consensus (11c)